APO Research
Talk to an analyst

APO RESEARCH · REPORT

Atypical Hemolytic Uremic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Atypical Hemolytic Uremic Syndrome Drug Market Analysis and Forecast 2026-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchAtypical Hemolytic Uremic Syndrome Drug Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Atypical Hemolytic Uremic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Atypical Hemolytic Uremic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Atypical Hemolytic Uremic Syndrome Drug Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Atypical Hemolytic Uremic Syndrome Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Atypical Hemolytic Uremic Syndrome Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Atypical Hemolytic Uremic Syndrome Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Atypical Hemolytic Uremic Syndrome Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Atypical Hemolytic Uremic Syndrome Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Atypical Hemolytic Uremic Syndrome Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Atypical Hemolytic Uremic Syndrome Drug include Amgen Inc, Omeros Corp, Kedrion SpA, greenovation Biotech GmbH, ChemoCentryx Inc, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc and Achillion Pharmaceuticals Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Atypical Hemolytic Uremic Syndrome Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Atypical Hemolytic Uremic Syndrome Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Atypical Hemolytic Uremic Syndrome Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Atypical Hemolytic Uremic Syndrome Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Atypical Hemolytic Uremic Syndrome Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Atypical Hemolytic Uremic Syndrome Drug sales, projected growth trends, production technology, application and end-user industry.

Atypical Hemolytic Uremic Syndrome Drug Segment by Company

Amgen Inc

Omeros Corp

Kedrion SpA

greenovation Biotech GmbH

ChemoCentryx Inc

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

Achillion Pharmaceuticals Inc

Atypical Hemolytic Uremic Syndrome Drug Segment by Type

OMS-72

Mubodina

ETR-001

ET-006

CCX-168

ALN-CC5

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Application

Clinic

Hospital

Others

Atypical Hemolytic Uremic Syndrome Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atypical Hemolytic Uremic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Atypical Hemolytic Uremic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atypical Hemolytic Uremic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Atypical Hemolytic Uremic Syndrome Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Atypical Hemolytic Uremic Syndrome Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Atypical Hemolytic Uremic Syndrome Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. OMS-72 Major Manufacturers Table 3. Mubodina Major Manufacturers Table 4. ETR-001 Major Manufacturers Table 5. ET-006 Major Manufacturers Table 6. CCX-168 Major Manufacturers Table 7. ALN-CC5 Major Manufacturers Table 8. Others Major Manufacturers Table 9. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 10. Clinic Major Manufacturers Table 11. Hospital Major Manufacturers Table 12. Others Major Manufacturers Table 13. Atypical Hemolytic Uremic Syndrome Drug Industry Trends Table 14. Atypical Hemolytic Uremic Syndrome Drug Industry Drivers Table 15. Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges Table 16. Atypical Hemolytic Uremic Syndrome Drug Industry Restraints Table 17. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 19. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 20. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2026) Table 21. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2027-2032) Table 22. Global Atypical Hemolytic Uremic Syndrome Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 23. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026) & (k units) Table 24. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2027-2032) & (k units) Table 25. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2026) Table 26. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2027-2032) Table 27. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 28. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Manufacturers (2021-2026) Table 29. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 30. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2021-2026) Table 31. Global Atypical Hemolytic Uremic Syndrome Drug Sales Price (US$/unit) of Manufacturers (2021-2026) Table 32. Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 33. Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters Table 34. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers, Product Type & Application Table 35. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers' Establishment Date Table 36. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 37. Global Atypical Hemolytic Uremic Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 38. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 40. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 41. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2026) Table 42. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2027-2032) Table 43. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 44. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 45. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 46. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2026) Table 47. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2027-2032) Table 48. Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2026) & (US$/unit) Table 49. Global Atypical Hemolytic Uremic Syndrome Drug Price by Type (2027-2032) & (US$/unit) Table 50. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 52. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 53. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2026) Table 54. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2027-2032) Table 55. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 56. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 57. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 58. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2026) Table 59. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2027-2032) Table 60. Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2026) & (US$/unit) Table 61. Global Atypical Hemolytic Uremic Syndrome Drug Price by Application (2027-2032) & (US$/unit) Table 62. Amgen Inc Company Information Table 63. Amgen Inc Business Overview Table 64. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 66. Amgen Inc Recent Development Table 67. Omeros Corp Company Information Table 68. Omeros Corp Business Overview Table 69. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 71. Omeros Corp Recent Development Table 72. Kedrion SpA Company Information Table 73. Kedrion SpA Business Overview Table 74. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 76. Kedrion SpA Recent Development Table 77. greenovation Biotech GmbH Company Information Table 78. greenovation Biotech GmbH Business Overview Table 79. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 81. greenovation Biotech GmbH Recent Development Table 82. ChemoCentryx Inc Company Information Table 83. ChemoCentryx Inc Business Overview Table 84. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 86. ChemoCentryx Inc Recent Development Table 87. Alexion Pharmaceuticals Inc Company Information Table 88. Alexion Pharmaceuticals Inc Business Overview Table 89. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 91. Alexion Pharmaceuticals Inc Recent Development Table 92. Akari Therapeutics Plc Company Information Table 93. Akari Therapeutics Plc Business Overview Table 94. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 96. Akari Therapeutics Plc Recent Development Table 97. Achillion Pharmaceuticals Inc Company Information Table 98. Achillion Pharmaceuticals Inc Business Overview Table 99. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio Table 101. Achillion Pharmaceuticals Inc Recent Development Table 102. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 105. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 106. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2021-2026) & (US$/unit) Table 107. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2027-2032) & (US$/unit) Table 108. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 111. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 112. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2021-2026) & (US$/unit) Table 113. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2027-2032) & (US$/unit) Table 114. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 116. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 117. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 118. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 119. North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 120. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2021-2026) & (US$/unit) Table 121. North America Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2027-2032) & (US$/unit) Table 122. United States Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 123. Canada Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 124. Mexico Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 125. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 126. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 127. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 128. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 129. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2021-2026) & (US$/unit) Table 130. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2027-2032) & (US$/unit) Table 131. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 134. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 135. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2021-2026) & (US$/unit) Table 136. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2027-2032) & (US$/unit) Table 137. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 139. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 140. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 141. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 142. Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 143. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2021-2026) & (US$/unit) Table 144. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2027-2032) & (US$/unit) Table 145. Germany Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 146. France Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 147. U.K. Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 148. Italy Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 149. Russia Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 150. Spain Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 151. Netherlands Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 152. Switzerland Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 153. Sweden Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 154. Poland Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 155. China Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. China Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. China Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 158. China Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 159. China Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2021-2026) & (US$/unit) Table 160. China Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2027-2032) & (US$/unit) Table 161. China Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. China Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. China Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 164. China Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 165. China Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2021-2026) & (US$/unit) Table 166. China Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2027-2032) & (US$/unit) Table 167. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 168. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 169. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 170. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 171. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2021-2026) & (US$/unit) Table 172. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2027-2032) & (US$/unit) Table 173. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 176. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 177. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2021-2026) & (US$/unit) Table 178. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2027-2032) & (US$/unit) Table 179. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 183. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 184. Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 185. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2021-2026) & (US$/unit) Table 186. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2027-2032) & (US$/unit) Table 187. Japan Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 188. South Korea Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 189. India Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 190. Australia Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 191. Taiwan Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 192. Southeast Asia Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 193. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2026) & (US$ Million) Table 194. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2027-2032) & (US$ Million) Table 195. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2026) & (k units) Table 196. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2027-2032) & (k units) Table 197. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2021-2026) & (US$/unit) Table 198. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Type (2027-2032) & (US$/unit) Table 199. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2026) & (US$ Million) Table 200. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2027-2032) & (US$ Million) Table 201. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2026) & (k units) Table 202. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2027-2032) & (k units) Table 203. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2021-2026) & (US$/unit) Table 204. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Application (2027-2032) & (US$/unit) Table 205. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 209. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021-2026) & (k units) Table 210. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2027-2032) & (k units) Table 211. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2021-2026) & (US$/unit) Table 212. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Price by Country (2027-2032) & (US$/unit) Table 213. Brazil Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 214. Argentina Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 215. Chile Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 216. Colombia Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 217. Peru Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 218. Saudi Arabia Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 219. Israel Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 220. UAE Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 221. Turkey Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 222. Iran Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 223. Egypt Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Table 224. Key Raw Materials Table 225. Raw Materials Key Suppliers Table 226. Atypical Hemolytic Uremic Syndrome Drug Distributors List Table 227. Atypical Hemolytic Uremic Syndrome Drug Customers List Table 228. Research Programs/Design for This Report Table 229. Authors List of This Report Table 230. Secondary Sources Table 231. Primary Sources List of Figures Figure 1. Atypical Hemolytic Uremic Syndrome Drug Image Figure 2. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. OMS-72 Image Figure 5. Mubodina Image Figure 6. ETR-001 Image Figure 7. ET-006 Image Figure 8. CCX-168 Image Figure 9. ALN-CC5 Image Figure 10. Others Image Figure 11. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Atypical Hemolytic Uremic Syndrome Drug Market Size Share 2021 VS 2025 VS 2032 Figure 13. Clinic Image Figure 14. Hospital Image Figure 15. Others Image Figure 16. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 18. Global Atypical Hemolytic Uremic Syndrome Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 20. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2032) Figure 21. Global Atypical Hemolytic Uremic Syndrome Drug Sales (2021-2032) & (k units) Figure 22. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 23. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2032) Figure 24. US & Canada & Mexico Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2021-2032) & (k units) Figure 25. Europe Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2021-2032) & (k units) Figure 26. China Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2021-2032) & (k units) Figure 27. Asia (Excluding China) Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2021-2032) & (k units) Figure 28. South America, Middle East and Africa Atypical Hemolytic Uremic Syndrome Drug Sales YoY (2021-2032) & (k units) Figure 29. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 30. Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 31. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 32. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 35. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 36. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 37. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032) Figure 38. Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 39. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 41. Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 42. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 43. Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032) Figure 44. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2032) Figure 45. North America Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2032) Figure 46. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2032) Figure 47. North America Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2032) Figure 48. North America Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2021-2032) Figure 49. North America Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2021-2032) Figure 50. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2032) Figure 51. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2032) Figure 52. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2032) Figure 53. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2032) Figure 54. Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2021-2032) Figure 55. Europe Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2021-2032) Figure 56. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2032) Figure 57. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2032) Figure 58. China Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2032) Figure 59. China Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2032) Figure 60. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2032) Figure 61. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2032) Figure 62. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2032) Figure 63. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2032) Figure 64. Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2021-2032) Figure 65. Asia Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2021-2032) Figure 66. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Type (2021-2032) Figure 67. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Share by Type (2021-2032) Figure 68. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Application (2021-2032) Figure 69. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Share by Application (2021-2032) Figure 70. SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Share by Country (2021-2032) Figure 71. SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales Share by Country (2021-2032) Figure 72. Atypical Hemolytic Uremic Syndrome Drug Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • OMS-72
  • Mubodina
  • ETR-001
  • ET-006
  • CCX-168
  • ALN-CC5
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Amgen Inc
  • Omeros Corp
  • Kedrion SpA
  • greenovation Biotech GmbH
  • ChemoCentryx Inc
  • Alexion Pharmaceuticals Inc
  • Akari Therapeutics Plc
  • Achillion Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Atypical Hemolytic Uremic Syndrome Drug Market by Type
  3. 1.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 OMS-72
  5. 1.2.3 Mubodina
  6. 1.2.4 ETR-001
  7. 1.2.5 ET-006
  8. 1.2.6 CCX-168
  9. 1.2.7 ALN-CC5
  10. 1.2.8 Others
  11. 1.3 Atypical Hemolytic Uremic Syndrome Drug Market by Application
  12. 1.3.1 Global Atypical Hemolytic Uremic Syndrome Drug Market Size by Application, 2021 VS 2025 VS 2032
  13. 1.3.2 Clinic
  14. 1.3.3 Hospital
  15. 1.3.4 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Atypical Hemolytic Uremic Syndrome Drug Market Dynamics
  1. 2.1 Atypical Hemolytic Uremic Syndrome Drug Industry Trends
  2. 2.2 Atypical Hemolytic Uremic Syndrome Drug Industry Drivers
  3. 2.3 Atypical Hemolytic Uremic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Atypical Hemolytic Uremic Syndrome Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region
  3. 3.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region
  9. 3.4.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers
  2. 4.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers
  6. 4.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Atypical Hemolytic Uremic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers, Product Type & Application
  13. 4.7 Global Atypical Hemolytic Uremic Syndrome Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Atypical Hemolytic Uremic Syndrome Drug Market CR5 and HHI
  16. 4.8.2 2025 Atypical Hemolytic Uremic Syndrome Drug Tier 1, Tier 2, and Tier 3
5 Atypical Hemolytic Uremic Syndrome Drug Market by Type
  1. 5.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type
  2. 5.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type
  6. 5.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Type
6 Atypical Hemolytic Uremic Syndrome Drug Market by Application
  1. 6.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application
  2. 6.1.1 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Atypical Hemolytic Uremic Syndrome Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application
  6. 6.2.1 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Atypical Hemolytic Uremic Syndrome Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Atypical Hemolytic Uremic Syndrome Drug Price by Application
7 Company Profiles
  1. 7.1 Amgen Inc
  2. 7.1.1 Amgen Inc Company Information
  3. 7.1.2 Amgen Inc Business Overview
  4. 7.1.3 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Amgen Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  6. 7.1.5 Amgen Inc Recent Developments
  7. 7.2 Omeros Corp
  8. 7.2.1 Omeros Corp Company Information
  9. 7.2.2 Omeros Corp Business Overview
  10. 7.2.3 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Omeros Corp Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  12. 7.2.5 Omeros Corp Recent Developments
  13. 7.3 Kedrion SpA
  14. 7.3.1 Kedrion SpA Company Information
  15. 7.3.2 Kedrion SpA Business Overview
  16. 7.3.3 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Kedrion SpA Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  18. 7.3.5 Kedrion SpA Recent Developments
  19. 7.4 greenovation Biotech GmbH
  20. 7.4.1 greenovation Biotech GmbH Company Information
  21. 7.4.2 greenovation Biotech GmbH Business Overview
  22. 7.4.3 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 greenovation Biotech GmbH Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  24. 7.4.5 greenovation Biotech GmbH Recent Developments
  25. 7.5 ChemoCentryx Inc
  26. 7.5.1 ChemoCentryx Inc Company Information
  27. 7.5.2 ChemoCentryx Inc Business Overview
  28. 7.5.3 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 ChemoCentryx Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  30. 7.5.5 ChemoCentryx Inc Recent Developments
  31. 7.6 Alexion Pharmaceuticals Inc
  32. 7.6.1 Alexion Pharmaceuticals Inc Company Information
  33. 7.6.2 Alexion Pharmaceuticals Inc Business Overview
  34. 7.6.3 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Alexion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  36. 7.6.5 Alexion Pharmaceuticals Inc Recent Developments
  37. 7.7 Akari Therapeutics Plc
  38. 7.7.1 Akari Therapeutics Plc Company Information
  39. 7.7.2 Akari Therapeutics Plc Business Overview
  40. 7.7.3 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Akari Therapeutics Plc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  42. 7.7.5 Akari Therapeutics Plc Recent Developments
  43. 7.8 Achillion Pharmaceuticals Inc
  44. 7.8.1 Achillion Pharmaceuticals Inc Company Information
  45. 7.8.2 Achillion Pharmaceuticals Inc Business Overview
  46. 7.8.3 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Achillion Pharmaceuticals Inc Atypical Hemolytic Uremic Syndrome Drug Product Portfolio
  48. 7.8.5 Achillion Pharmaceuticals Inc Recent Developments
8 North America
  1. 8.1 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
  2. 8.1.1 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
  5. 8.2 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
  6. 8.2.1 North America Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
  9. 8.3 North America Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
  10. 8.3.1 North America Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Atypical Hemolytic Uremic Syndrome Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
  2. 9.1.1 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
  5. 9.2 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
  6. 9.2.1 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
  9. 9.3 Europe Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
  10. 9.3.1 Europe Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Atypical Hemolytic Uremic Syndrome Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
  2. 10.1.1 China Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  4. 10.1.3 China Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
  5. 10.2 China Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
  6. 10.2.1 China Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 10.2.3 China Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
  2. 11.1.1 Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
  5. 11.2 Asia Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
  6. 11.2.1 Asia Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
  9. 11.3 Asia Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
  10. 11.3.1 Asia Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Atypical Hemolytic Uremic Syndrome Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Atypical Hemolytic Uremic Syndrome Drug Market Size by Type
  2. 12.1.1 SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Atypical Hemolytic Uremic Syndrome Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Atypical Hemolytic Uremic Syndrome Drug Market Size by Application
  6. 12.2.1 SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Atypical Hemolytic Uremic Syndrome Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Atypical Hemolytic Uremic Syndrome Drug Market Size by Country
  10. 12.3.1 SAMEA Atypical Hemolytic Uremic Syndrome Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Atypical Hemolytic Uremic Syndrome Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Atypical Hemolytic Uremic Syndrome Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Atypical Hemolytic Uremic Syndrome Drug Value Chain Analysis
  2. 13.1.1 Atypical Hemolytic Uremic Syndrome Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Atypical Hemolytic Uremic Syndrome Drug Production Mode & Process
  6. 13.2 Atypical Hemolytic Uremic Syndrome Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Atypical Hemolytic Uremic Syndrome Drug Distributors
  9. 13.2.3 Atypical Hemolytic Uremic Syndrome Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst